BioLineRx (BLRX) PT Lowered to $2 at Maxim Group

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/17/2026

1. VRNS
2. CRWV
3. JBHT
4. TSLA
5. SCHW
6. GPRK
7. TRV
8. TFC
9. PNC
10. NEST:IN

Go back to BioLineRx (BLRX) PT Lowered to $2 at Maxim Group

BioLineRx Reports Year End 2017 Financial Results

March 6, 2018 7:00 AM EST

TEL AVIV, Israel, March 6, 2018 /PRNewswire/ --

BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, today reports its financial results for the year ended December 31, 2017.

Highlights and achievements in 2017 and to date:

Continued progress and execution according to plan on multiple clinical trials for the Company's lead oncology program, BL-8040:

Initiation of pivotal Phase 3 GENESIS study with BL-8040 as novel stem cell mobilization treatment for autologous bone-marrow transplantation, following successful meeting with the FDA earlier in the... More